Meilleure Health International Industry Group Limited: Key Resolutions Passed at SGM

SGM Approves Major Transaction and Share Award Scheme

Meilleure Health International Industry Group Limited (Stock code: 2327) has announced the results of its Special General Meeting (SGM) held on 21 April 2026, where shareholders voted on several resolutions with potentially significant implications for the Company’s future direction and share value.

Key Points from the SGM

• Discloseable and Connected Transaction: The SGM approved the Equity Interest Transfer Agreement, a key transaction that involves the transfer of equity interests between the Company and certain vendors. This transaction was categorized as both a discloseable and connected transaction, signaling its materiality and the involvement of connected parties.
• Adoption of 2026 Share Award Scheme: Shareholders also approved the implementation of the 2026 Share Award Scheme, a move aimed at aligning the interests of employees, directors, and service providers with the long-term growth of the Company.
• Shareholder Participation and Voting: The total number of shares in issue (excluding treasury shares) stood at 4,088,428,636. Notably, Mr. Zhou, Ms. Zhou, and their respective associates, collectively holding approximately 63.60% of the issued share capital, abstained from voting on the resolution related to the Equity Interest Transfer Agreement due to their material interest. This left 1,488,260,875 shares (36.40%) eligible to vote on this resolution.
• Poll Results: The poll was conducted by Tricor Investor Services Limited. All resolutions were passed by a significant majority:
  • Equity Interest Transfer Agreement and related authorizations: 100% in favor (131,073,997 votes), 0% against
  • 2026 Share Award Scheme (including 10% share limit and 1% service provider sublimit): 99.98% in favor (2,682,204,288 votes), 0.02% against (558,000 votes)
• Director Attendance: All current directors, including executive, non-executive, and independent non-executive directors, attended the SGM, reflecting strong governance and oversight.

Potential Price-Sensitive Information

• Approval of the Equity Interest Transfer Agreement: The transaction’s approval could signal strategic expansion, asset restructuring, or partnership initiatives, which may impact the Company’s future earnings and valuation.
• 2026 Share Award Scheme: With up to 10% of the issued share capital (as of the effective date) available for share awards, the scheme may result in share dilution but is designed to incentivize key personnel and service providers. The introduction of a 1% sublimit for service providers ensures a cap on awards outside employees/directors, aligning with best practices.
• Strong Shareholder Support: The overwhelming support for all resolutions indicates robust confidence from the independent shareholders and may be viewed positively by the market.
• Connected Parties Abstention: The abstention of major shareholders due to connected interests highlights transparency and adherence to corporate governance standards.

What Investors Should Watch

• Implementation of the Equity Interest Transfer Agreement: Investors should monitor further announcements regarding the completion and financial impact of the transaction.
• Details of the Share Award Scheme: The market may react to future disclosures on the recipients of share awards and the resulting dilution effects.
• Regulatory Approvals: The implementation of the Share Award Scheme is conditional upon Stock Exchange approval for the listing of new shares.

Conclusion

The SGM results mark a significant step for Meilleure Health International Industry Group Limited, with shareholders endorsing both a strategic transaction and a new share-based incentive scheme. Both actions are likely to impact the Company’s structure, strategic direction, and shareholding dynamics, and could therefore be price-sensitive in the short to medium term.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should independently assess the implications of the SGM results and consult with their professional advisors before making investment decisions. The author and publisher are not responsible for any financial losses resulting from actions taken based on the contents of this article.

View MEILLEUREHEALTH Historical chart here